Literature DB >> 33470952

Delayed treatment of bacteremia during the COVID-19 pandemic.

Taiju Miyagami1, Yuki Uehara1,2, Taku Harada3,4, Takashi Watari5, Taro Shimizu4, Ayako Nakamura6, Naoya Ogura6, Seiko Kushiro1, Katsutoshi Masuyama1, Yoshinori Kanai1, Kwang-Seok Yang1, Toshio Naito1.   

Abstract

OBJECTIVES: Coronavirus disease (COVID-19) blindness, that is, the excessive consideration of the disease in diagnosis, has reportedly led to delayed diagnosis of some diseases. We compared several clinical measures between patients admitted for bacteremia during the two months of the COVID-19 pandemic and those admitted during the same period in 2019. We hypothesized that the pandemic has led to delayed treatment of bacteremia.
METHODS: This retrospective observational study compared several measures undertaken for patients who visited the emergency unit in two hospitals between March 1 and May 31, 2020, during the COVID-19 pandemic and whose blood cultures tested positive for bacteremia with those for corresponding patients treated during the same period in 2019. The primary measure was time from consultation to blood culture/antimicrobials.
RESULTS: We included 29 eligible patients from 2020 and 26 from 2019. In 2020, the time from consultation to antimicrobial administration was significantly longer than in 2019 (mean [range], 222 [145-309] min vs. 139 [102-179] min, p=0.002). The frequency of chest computed tomography (CT) was significantly higher in 2020 (96.6 vs. 73.1%, p=0.021). Significant differences were not observed in the time to blood culture or chest CT preceding the blood culture between the two periods.
CONCLUSIONS: Our findings suggested that due to the COVID-19 epidemic/pandemic, focusing on the exclusion of its infection using CT scans leads to an overall delay in the diagnosis and treatment of bacteremia. Medical providers must be aware of COVID-19 blindness and evaluate patients objectively based on rational criteria and take appropriate action.
© 2020 Walter de Gruyter GmbH, Berlin/Boston.

Entities:  

Keywords:  COVID-19; COVID-19 blindness; bacteremia

Year:  2021        PMID: 33470952     DOI: 10.1515/dx-2020-0114

Source DB:  PubMed          Journal:  Diagnosis (Berl)        ISSN: 2194-802X


  4 in total

1.  A Direct Rapid Phenotypic Antimicrobial Susceptibility Test Enables Early Selection of Optimal Antibiotics to Treat Bacteremia in COVID-19 Patients.

Authors:  Taek Soo Kim; Wan Beom Park; Do Hyeon Park; Euijin Chang; Chang Kyung Kang; Pyoeng Gyun Choe; Nam Joong Kim; Myoung-Don Oh
Journal:  Infect Chemother       Date:  2021-12

2.  Diagnosing Bacterial Infection in the era of Pandemic: A Case Report.

Authors:  Junki Mizumoto; Hirohisa Fujikawa
Journal:  Cureus       Date:  2022-02-24

3.  Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19.

Authors:  Nicholas Rebold; Sara Alosaimy; Taylor Morrisette; Dana Holger; Abdalhamid M Lagnf; Iman Ansari; Ana C Belza; Laura Cheaney; Huzaifa Hussain; Shelbye R Herbin; Jacinda Abdul-Mutakabbir; Caitlin Carron; Avnish Sandhu; Teena Chopra; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2022-05-11

4.  Bloodstream Infections in a COVID-19 Non-ICU Department: Microbial Epidemiology, Resistance Profiles and Comparative Analysis of Risk Factors and Patients' Outcome.

Authors:  Efthymia Giannitsioti; Christina Louka; Vasiliki Mamali; Elisavet Kousouli; Lemonia Velentza; Vaia Papadouli; Georgios Loizos; Panagiotis Mavroudis; Georgios Kranidiotis; Nektaria Rekleiti; Alexandra Stamati; Ioannis Speggos; Ioannis Daniil; Panagiotis Kouvatsos; Chrysanthi Sidiropoulou; Garifallia Linardaki; Styliani Gerakari; Georgios Chrysos; Katina Themeli-Digalaki; Olympia Zarkotou
Journal:  Microorganisms       Date:  2022-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.